Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | FNTA | P49354 | 3/20 | 0.37 |
| ▸ | FNTB | P49356 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KDM6B | O15054 | 1/20 | 0.35 |
| ▸ | KDM5C | P41229 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15363969 | 0.88 | TSHR (0.45) | TSHRFNTAFNTBLMNAKDM4E | |
| SCHEMBL15363964 | 0.86 | TSHR (0.44) | TSHRLMNAALDH1A1ATMFFAR1 | |
| SCHEMBL31547210 | 0.86 | TSHR (0.44) | TSHRLMNAALDH1A1ATMFFAR1 | |
| SCHEMBL811740 | 0.85 | PPARG (0.46) | TSHRLMNAALDH1A1ATMMAPT | |
| SCHEMBL810942 | 0.85 | PPARG (0.46) | TSHRLMNAALDH1A1ATMMAPT | |
| SCHEMBL28451720 | 0.80 | CYP2D6 (0.48) | EGLN1FNTAFNTBLMNAALDH1A1 | |
| SCHEMBL22917083 | 0.80 | LMNA (0.38) | TSHRFNTAFNTBLMNAALDH1A1 | |
| SCHEMBL1578474 | 0.80 | FNTA (0.35) | FNTAFNTBLMNASLC15A2KDM4E | |
| SCHEMBL4772516 | 0.79 | ALOX15 (0.53) | FNTAFNTBKDM4EALDH1A1ATM | |
| SCHEMBL28451722 | 0.79 | FNTA (0.38) | FNTAFNTBLMNASLC15A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107257813-B | Block copolymers having surface active anchoring groups, compositions and methods thereof | AZ电子材料卢森堡有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-8975267-B2 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-10 | — | — | US | disclosed |
| US-20130296305-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-07 | — | — | US | disclosed |
| EP-2389349-A2 | METHODS FOR PRODUCING DODECANEDIOIC ACID AND DERIVATIVES THEREOF | Draths Corporation (US) | 2011-11-30 | — | — | EP | disclosed |
| US-8041434-B2 | Implantable medical electrical lead bodies providing improved electrode contact | MEDTRONIC, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2010085712-A2 | METHODS FOR PRODUCING DODECANEDIOIC ACID AND DERIVATIVES THEREOF | DRATHS CORPORATION (US) | 2010-07-29 | — | — | WO | disclosed |
| EP-0938465-B1 | CROSS-DIMERIZATION OF OLEFINS | DU PONT (US) | 2001-12-12 | — | — | EP | disclosed |
| EP-0938465-A1 | CROSS-DIMERIZATION OF OLEFINS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5892101-A | USING COORDINATION CATALYST; REACTING METHYL ACRYLATE WITH ETHYLENE TO GIVE METHYL 4-PENTENOATE; NYLON CHEMICAL INTERMEDIATE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1998022424-A1 | CROSS-DIMERIZATION OF OLEFINS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-05-28 | — | — | WO | disclosed |
| US-4638084-A | BIS (THYLENE) RHODIUM TETRAFLUOROBORATE CATALYST | SHELL OIL COMPANY (US) | 1987-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296305-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | TSHR 3340/4885EGLN1 2502/4885FNTA 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.